We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $11.1B
1-Year Est. Return 207.82%
This Fund
S&P 500
This Quarter Est. Return
-16.36%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$1.67B
AUM Growth
-$505M
Cap. Flow
-$94.1M
Cap. Flow %
-5.62%
Top 10 Hldgs %
75.72%
Holding
51
New
6
Increased
12
Reduced
12
Closed
16

Top Buys

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$49.3M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$41.5M
3
ALLO icon
Allogene Therapeutics
ALLO
+$30M
4
AMRN
Amarin Corp
AMRN
+$27.9M
5
ZGNX
Zogenix, Inc.
ZGNX
+$21.2M

Top Sells

Rank Stock Value
1
ECYT
Endocyte, Inc. Common Stock
ECYT
+$94.2M
2
PBYI icon
Puma Biotechnology
PBYI
+$52.8M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$36.8M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$33.7M
5
CPRX
Catalyst Pharmaceutical
CPRX
+$17M

Sector Composition

Rank Sector Weight
1 Healthcare 99.76%
2 Miscellaneous 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FENC icon
26
Fennec Pharmaceuticals
FENC
$373M
$7.06M 0.42%
1,105,999
+83,333
+8% +$582K
KOD icon
27
Kodiak Sciences
KOD
$2.07B
$6.41M 0.38%
+902,200
New +$7.99M
YMAB
28
DELISTED
Y-mAbs Therapeutics
YMAB
$6.3M 0.38%
310,000
– –
ALIM
29
DELISTED
Alimera Sciences
ALIM
$4.48M 0.27%
416,000
-105
-0% -$1.53K
KA
30
DELISTED
Kineta, Inc. Common Stock
KA
$4.21M 0.25%
+9,286
New +$6.29M
ACER
31
DELISTED
Acer Therapeutics Inc
ACER
$3.02M 0.18%
150,000
-130,000
-46% -$2.99M
XBI icon
32
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$1.44M 0.09%
+500,000
New +$40.3M
OTLK icon
33
Outlook Therapeutics
OTLK
$164M
$340K 0.02%
4,250
-22
-0.5% -$2.71K
NBIX icon
34
CALL
Neurocrine Biosciences
NBIX
$15.2B
$15K ﹤0.01%
+50,000
New +$4.79M
ACAD icon
35
Acadia Pharmaceuticals
ACAD
$4.61B
– –
-100,000
Closed -$2.08M
ARWR icon
36
Arrowhead Research
ARWR
$9.98B
– –
-849,899
Closed -$16.3M
CARM
37
DELISTED
Carisma Therapeutics
CARM
– –
-340,000
Closed -$14.6M
CPRX
38
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-4,497,042
Closed -$17M
CRSP icon
39
CRISPR Therapeutics
CRSP
$5.01B
– –
-147,368
Closed -$6.54M
DBVT
40
DBV Technologies
DBVT
$739M
– –
-5,400
Closed -$1.21M
PBYI icon
41
Puma Biotechnology
PBYI
$477M
– –
-1,150,685
Closed -$52.8M
QQQ icon
42
PUT
Invesco QQQ Trust
QQQ
$474B
– –
-500,000
Closed -$175K
VNDA icon
43
Vanda Pharmaceuticals
VNDA
$302M
– –
-430,000
Closed -$9.87M
XBI icon
44
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-1,500,000
Closed -$1.18M
CLVS
45
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-1,146,636
Closed -$33.7M
PRNB
46
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
– –
-75,000
Closed -$2.19M
ONCS
47
DELISTED
OncoSec Medical Incorporated
ONCS
– –
-2,273
Closed -$700K
TSRO
48
DELISTED
TESARO, Inc.
TSRO
– –
-150,000
Closed -$5.85M
ECYT
49
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-5,301,718
Closed -$94.2M
ONSIW
50
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
– –
-233,333
Closed -$3K
1
2

Similar funds

GI
GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
LCAM
London & Capital Asset Management London, United Kingdom $10.9B AUM 39.88% 1-Year Est. Return

Avoro Capital Advisors's Q4 2018 Portfolio in Review

As of Q4 2018, Avoro Capital Advisors held 51 positions worth $1.67B, down 23% from $2.18B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Avoro Capital Advisors withdrew a net $94.1M in Q4 2018, closing 16 positions and reducing 12 holdings. Its most notable exit was Endocyte, Inc. Common Stock, an estimated $94.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Avoro Capital Advisors opened a new position in Loxo Oncology, Inc worth $45.5M.

  • Avoro Capital Advisors's largest Q4 2018 buy was Loxo Oncology, Inc: 325,000 shares worth $45.5M.
  • Avoro Capital Advisors added most to Sarepta Therapeutics in Q4 2018, an estimated $41.5M increase.
  • Avoro Capital Advisors's biggest Q4 2018 reduction was Madrigal Pharmaceuticals, cutting an estimated $36.8M.
  • Avoro Capital Advisors fully exited Endocyte, Inc. Common Stock in Q4 2018, selling an estimated $94.2M.
  • Avoro Capital Advisors's ten largest holdings make up 76% of its $1.67B portfolio in Q4 2018.
  • Avoro Capital Advisors opened 6 new positions and closed 16 in Q4 2018.
  • Avoro Capital Advisors's portfolio value fell 23% quarter-over-quarter to $1.67B.

Based on Avoro Capital Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.